monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
Published 6 years ago • 725 plays • Length 4:54Download video MP4
Download video MP3
Similar videos
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
8:30
cdk4/6 inhibitors in er metastatic breast cancer during the covid-19 pandemic
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:07
sequencing first-line cdk4/6 inhibitors in metastatic breast cancer
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
2:31
cdk4/6 inhibitors: a hot topic in breast cancer treatment
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
0:49
breast cancer at esmo 2023: adcs and monarch 3
-
5:37
metastatic breast cancer at esmo 2022: tropics02, monarch 3 and synergy
-
2:30
clinical trials in breast cancer: pallas, monarch 3 and solar-1
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
6:15
breast cancer at esmo 2020: cdk4/6 inhibitors and checkpoint inhibitors
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
3:35
the benefits of adjuvant cdk4/6 and parp inhibition in breast cancer
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer